Premium
Treatment accuracy and patient pain compared in Retinal Navigated Laser (Navilas®) versus conventional laser in diabetic macular edema
Author(s) -
KERNT M,
ULBIG MW,
KAMPIK A,
NEUBAUER AS
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.2214.x
Subject(s) - medicine , visual analogue scale , laser , diabetic macular edema , ophthalmology , retinal , laser treatment , pain score , edema , macular edema , diabetic retinopathy , visual acuity , laser therapy , surgery , diabetes mellitus , physics , optics , endocrinology
Purpose Treatment accuracy and patient pain were evaluated using a novel navigating laser (NAVILAS) compared to conventional laser treatment in clinically significant macular edema (CSME). Methods Focal Navilas laser was performed in 42 patients. On color images (CI) and OCT laser spots were analyzed regarding accuracy spot placement compared to planning. Treatment pain was quantified on a visual‐analogue‐scale (VAS) and compared to a matched control. Up to one year clinical follow‐up investigated retreatment and visual acuity compared to a control of 113 patients treated by conventional laser. Results 79% of laserspots were visible on CI, of which 96% were within 100µm from the planned target. OCT confirmed that laser effects were limited to the outer retina . The number of laser spots per patient was 115+/‐97 with Navilas, (43+/‐36) with conventional laser. Pain on VAS was mean 1.6 (SD 1.0), 4.4 (SD 1.8) for the control. Kaplan‐Meier analysis showed separation of the retreatment curves after 4‐5 months with less retreatments for Navilas. Conclusion Compared to conventional laser, significantly more laserspots were placed with Navilas, patient reported pain was significantly lower. the tendency for lower retreatment rates tend with Navilas may be important when considering possible combination laser and anti‐VEGF drug therapy.Commercial interest